...bring a wide spectrum of scientific and clinical experience to the development effort...
Scottsdale, AZ (PRWEB) July 14, 2012
QualityStocks would like to highlight RXi Pharmaceuticals Corporation, a publicly traded biotechnology company focused on discovering, developing, and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to “silence,” or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.
In the company’s news yesterday,
Biotech company RXi Pharmaceuticals announced Dr. Jeannette Graf and Dr. Leroy Young have been added to its Scientific Advisory Board where their experience and research expertise will contribute to the ongoing development of the company’s lead compound.
Dr. Graf is a board certified, clinical and research dermatologist with a private practice in Great Neck, NY. She is an assistant clinical professor of Dermatology at the Mount Sinai School of Medicine in New York; an accomplished product developer; and author of best-selling Stop Aging, Start Living. Dr. Graf has made multiple television and news appearances on national news and popular cable programs including: The Dr. Oz Show, Fox And Friends, MSNBC, The View, Inside Edition, Focus On Women, CBS Early Show, Good Morning America, Mike and Juliet, and Sirius Radio. In addition, she is quoted in numerous national print and online publications.
Dr. Young is the director of the BodyAesthetic Research Center in St. Louis, Missouri. He is board certified in General Surgery and Plastic Surgery, and has held several academic positions in the fields of surgery and plastic surgery at the Washington School of Medicine in St. Louis Missouri. Dr. Young is also the author of numerous patents and publications.
RXI-109, currently in phase I clinical study, is RXi Pharmaceuticals’ self-delivering RNAi compound (sd-rxRNA®) developed to reduce dermal scarring in planned surgeries. The addition of Dr. Graf and Dr. Young strengthen the company’s advisory board as it guides continued research and development of RXI-109.
“Dr. Graf and Dr. Young are notable additions to our Scientific Advisory Board,” Dr. Geert Cauwenbergh, president and CEO of RXi Pharmaceuticals stated in the press release. “Together Dr. Young and Dr. Graf bring a wide spectrum of scientific and clinical experience to the development effort that RXi has underway with RXI-109, the first self-delivering RNAi to enter into clinical development. In addition, they also bring a unique understanding of the cosmetic surgery and dermatology space, with in-depth knowledge of the need gaps that still exist today in the management of scarring.”
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.